How to Track Dose Escalation Protocols Accurately

Why dose escalation makes tracking harder

A protocol that stays at one dose is straightforward to track: same compound, same dose, same schedule. But GLP-1 protocols (tirzepatide, semaglutide) and some peptide protocols involve deliberate dose escalation — starting low and stepping up every 4 weeks.

Dose escalation introduces two tracking problems that don't exist in flat protocols:

1. The units-to-draw change at each step. If your concentration stays the same but your dose goes from 2.5 mg to 5 mg, you now draw twice as many units. If your concentration also changes (different vial strength), the calculation changes again. Mixing up which draw amount corresponds to which dose step is a significant error source.
2. The escalation history matters clinically. Your prescribing provider needs to know when you escalated, how you tolerated each step, and whether you ever stepped back. A notes-app log of "took tirzepatide this week" without dose level is clinically useless.

What a good escalation log captures

For each injection in an escalation protocol, the record should include:

• Date and time of injection
• Dose amount (mg or mcg, not just units)
• Units drawn (so the calculation is auditable)
• Vial lot or reconstitution batch (to correlate with any quality issues)
• Injection site
• Any notable side effects or tolerance observations

The dose amount in mg matters more than the units. Units are a function of vial concentration; if you switch to a different vial concentration, the units change but the dose doesn't. A provider reviewing your history needs to see mg/dose, not syringe marks.

Standard tirzepatide escalation: units at each step

For a compounded tirzepatide vial at 5 mg/mL concentration:

At a different concentration (e.g., 10 mg/mL), all unit values are halved. Use the reconstitution calculator to get the correct units for your actual vial concentration at each dose step.

When escalation stalls: tracking a hold or step-back

GLP-1 escalation protocols include the option to hold at a dose level longer than 4 weeks, or to step back to the previous dose if side effects are intolerable. Both are clinically valid and require clear documentation.

A dose log that shows "held at 2.5 mg for 8 weeks instead of escalating at week 4" gives the provider context for whether the current dose is achieving the intended therapeutic effect and whether to escalate or adjust. Without the log, this history is lost.

Multi-compound escalation: the hardest tracking scenario

Running tirzepatide escalation simultaneously with a TB-500 loading phase means two concurrent escalation/loading curves with different step schedules. Add CJC-1295/Ipamorelin and you have three compounds with different cadences.

The only reliable way to track this is a purpose-built tracker that stores the full dose history per compound with actual amounts — not a shared calendar or notes app where you lose the dose-level context.

My Pep Calc stores each dose log with compound, amount, date, site, and notes. The escalation history is always queryable — you and your provider can scroll through the full timeline of every dose at every level, not just the current step.

The clinical visit use case

"How are you tolerating it?" and "When did you escalate?" are the two most common clinical questions at follow-up visits during a GLP-1 protocol. A complete dose log answers both with precision: exact escalation dates, any holds, any side effect notes, and current dose. A provider making a decision on whether to continue escalating, hold, or step back needs that data — not an estimate.